Burden of Oral Mucositis: A Systematic Review and Implications for Future Research

被引:71
作者
Berger, Karin [1 ]
Schopohl, Dorothee [1 ]
Bollig, Antonia [1 ]
Strobach, Dorothea [2 ]
Rieger, Christina [1 ]
Rublee, Dale
Ostermann, Helmut [1 ]
机构
[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, Munich, Germany
[2] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Pharm, Munich, Germany
关键词
Epidemiology; Health economics; Mucositis; Quality of life; Supportive care; QUALITY-OF-LIFE; STEM-CELL TRANSPLANTATION; METASTATIC BREAST-CANCER; NECK-CANCER; ECONOMIC OUTCOMES; ADVERSE EVENTS; RETROSPECTIVE ANALYSIS; COST-EFFECTIVENESS; MYELOMA PATIENTS; SUPPORTIVE CARE;
D O I
10.1159/000487085
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Surprisingly little is known about the burden of oral mucositis (OM). We provide a systematic review of studies on the burden of OM (incidence, economic impact, health-related quality of life (HRQoL)). Methods: Systematic literature searches were made in BIOSIS, EMBASE, and MEDLINE. Inclusion criteria were studies on OM in hematology/oncology patients of >= 18 years, journal articles, English language, and published between 2000 and 2016; OM treatment studies were excluded. Quality assessment was performed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Results: We screened 4,996 hits, and identified 68 studies of which 13 were without transparency on OM grading. The evidence level of 65 studies was rated 'low' or 'very low' in 58.5%, 'moderate' in 20% and 'high' in 21.5%. Mean value of incidence (7 studies) was 83.5% for all grades of OM with hematopoietic stem cell transplantation. OM incidence for all grades in head and neck cancer patients was 59.4-100%. Considering the economic impact, 16 studies showed highly variable numbers. HRQoL was measured in 16 studies using 13 different instruments. Statistically significant changes in HRQoL scores were demonstrated. Conclusion: OM is common, burdensome, costly and imposes major reductions in HRQoL. However, from a quality standpoint, the level of current evidence in OM is disappointing. The field needs continued attention to address methodological challenges. (c) 2018 S. Karger GmbH, Freiburg
引用
收藏
页码:399 / 405
页数:7
相关论文
共 74 条
[1]  
Al Ibraheemi Ahmed A, 2016, Int J Hematol Oncol Stem Cell Res, V10, P217
[2]  
Al-Ansari Sali, 2015, Curr Oral Health Rep, V2, P202
[3]   The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax) [J].
Al-Batran, S. -E. ;
Hozaeel, W. ;
Tauchert, F. K. ;
Hofheinz, R. -D. ;
Hinke, A. ;
Windemuth-Kieselbach, C. ;
Huebner, A. ;
Burmester, M. ;
Koenigsmann, M. ;
Wiegand, J. ;
zur Hausen, G. ;
Linsse, B. ;
Kuhl, R. ;
Pauligk, C. .
ANNALS OF ONCOLOGY, 2015, 26 (06) :1244-1248
[4]   CD34+selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation [J].
Anand, Ankit ;
Anandi, Prathima ;
Jain, Natasha A. ;
Lu, Kit ;
Dunavin, Neil ;
Hourigan, Christopher S. ;
Le, Robert Q. ;
Chokshi, Puja D. ;
Ito, Sawa ;
Stroncek, David F. ;
Sabatino, Marianna ;
Barrett, A. John ;
Battiwalla, Minoo .
SUPPORTIVE CARE IN CANCER, 2016, 24 (02) :815-822
[5]   GRADE guidelines: 3. Rating the quality of evidence [J].
Balshem, Howard ;
Helfand, Mark ;
Schuenemann, Holger J. ;
Oxman, Andrew D. ;
Kunz, Regina ;
Brozek, Jan ;
Vist, Gunn E. ;
Falck-Ytter, Yngve ;
Meerpohl, Joerg ;
Norris, Susan ;
Guyatt, Gordon H. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2011, 64 (04) :401-406
[6]   Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain [J].
Banz, Kurt ;
Bischoff, Helge ;
Brunner, Matthias ;
Chouaid, Christos ;
de Castro Carpeno, Javier ;
de Marinis, Filippo ;
Grossi, Francesco ;
Vergnenegre, Alain ;
Walzer, Stefan .
LUNG CANCER, 2011, 74 (03) :529-534
[7]   Cost-effectiveness of the introduction of specialized oral care with laser therapy in hematopoietic stem cell transplantation [J].
Bezinelli, Leticia Mello ;
Eduardo, Fernanda de Paula ;
da Graca Lopes, Roberta Marques ;
Haye Biazevic, Maria Gabriela ;
Eduardo, Carlos de Paula ;
Correa, Luciana ;
Hamerschlak, Nelson ;
Michel-Crosato, Edgard .
HEMATOLOGICAL ONCOLOGY, 2014, 32 (01) :31-39
[8]   Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial [J].
Bonner, James A. ;
Giralt, Jordi ;
Harari, Paul M. ;
Baselga, Jose ;
Spencer, Sharon ;
Bell, Diana ;
Raben, David ;
Liu, Joyce ;
Schulten, Jeltje ;
Ang, Kian K. ;
Rosenthal, David I. .
EUROPEAN JOURNAL OF CANCER, 2016, 64 :1-11
[9]   Assessment of Anxiety and Depression in Oral Mucositis Patients Undergoing Cancer Chemoradiotherapy: A Randomized Cross-sectional Study [J].
Chaitanya, Nallan C. S. K. ;
Garlapati, Komali ;
Priyanka, Danam Reshma ;
Soma, Sravani ;
Suskandla, Ujwala ;
Boinepally, Niharika Harsha .
INDIAN JOURNAL OF PALLIATIVE CARE, 2016, 22 (04) :446-454
[10]   The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review [J].
Chaudhry, Hafsa M. ;
Bruce, Alison J. ;
Wolf, Robert C. ;
Litzow, Mark R. ;
Hogan, William J. ;
Patnaik, Mrinal S. ;
Kremers, Walter K. ;
Phillips, Gordon L. ;
Hashmi, Shahrukh K. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (04) :605-616